Treatment
Cell clinical trials
We’re tracking 5,550 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT05868395RecruitingPhase 2
Treating relapsed mantle cell lymphoma with three drug combination
This Phase 2 study tests how well polatuzumab combined with bendamustine and rituximab works for mantle cell lymphoma that has come back or not responded. It may help shrink tumors and improve disease control, especially after prior treatment with ibrutinib.
ViennaAges 18–100 - NCT06256237RecruitingPhase 2
Immunotherapy plus chemo before surgery for limited-stage small cell lung cancer
This trial tests whether adding two immunotherapy drugs (toripalimab and JS004) to standard chemotherapy before surgery can help shrink limited-stage small cell lung cancer. The goal is to find better ways to treat this cancer before surgery.
ShanghaiAges 18 years+ - NCT06423131Recruiting
Comparing two types of stem cell transplants for children
This study compares a newer type of stem cell transplant (using special cells) to the standard method for children who need a half-matched donor. It aims to see if the new approach is safer and works as well.
Shanghai, Shanghai MunicipalityAges 2 months–18 years - NCT06109558RecruitingPhase 1/Phase 2
LMV-12 plus Osimertinib for advanced lung cancer
This trial tests a new drug called LMV-12 combined with osimertinib for people with advanced non-small cell lung cancer that has certain genetic changes (MET amplification or RET fusion) and has stopped responding to standard EGFR inhibitor treatments.
Changsha, HunanAges 18 years+ - NCT06004154Recruiting
Imaging follow-up for giant cell arteritis patients
This study follows up patients with giant cell arteritis (Horton's disease) using MRI and ultrasound to see how the disease and treatment affect blood vessels over time. It aims to improve understanding of the condition and your imaging results.
ParisAges 50 years+ - NCT07847190RecruitingPhase 2
Adding paclitaxel to standard chemotherapy for tough testicular cancer
This trial tests if adding a drug called paclitaxel to the standard chemotherapy combination (BEP) can improve outcomes for people with aggressive testicular cancer. It is for those whose tumor markers did not drop as fast as expected after the first round of chemo.
MoscowAges 16 years+ - NCT05933434RecruitingPhase 1/Phase 2
Stem cell injection trial for chronic knee osteoarthritis
This early-phase study tests an injection of donor stem cells placed into the knee joint to help reduce symptoms of knee osteoarthritis. You may be eligible if you have long-lasting knee pain from mild-to-moderate arthritis and meet safety and imaging requirements.
Aarhus NAges 40–75 - NCT06462248RecruitingPhase 2
CAR-T therapy for B-cell blood cancers
This trial tests a new CAR-T cell therapy that targets a protein called CD19 on B-cell cancer cells. It is for children and adults with B-cell acute lymphoblastic leukemia or certain B-cell lymphomas that have not improved with standard treatments.
Hong KongAges 1 year+ - NCT06461182RecruitingPhase 2
PET Scan Test for Slow-Growing Lymphoma
This trial uses a special PET scan to take detailed pictures of slow-growing lymphomas, likely before or after your regular treatment scan. It may help your doctor see exactly where the lymphoma is in your body.
Taipei, BeitouAges 20–100 - NCT06464068RecruitingPhase 2
Immunotherapy plus chemo for first-line advanced extrapulmonary small cell cancer
This trial tests a new combination of durvalumab (an immunotherapy) plus standard chemotherapy for people with advanced small cell carcinoma that started outside the lung and has not been treated before. The goal is to see if this combo works better than chemo alone.
Reggio EmiliaAges 18 years+ - NCT06463834RecruitingPhase 2
Sintilimab plus chemo before surgery for esophageal cancer
This study tests a combination of an immunotherapy drug (sintilimab) with chemotherapy given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Fuzhou, FujianAges 18–75 - NCT03786549Recruiting
Sickle cell care transition program for teens and families
This study tests a structured program to help teens with sickle cell disease smoothly transition from pediatric care to adult care, with support for parents or legal guardians. It may help families coordinate care sooner and more confidently during this change.
Fort-de-France-La Martinique, La MartiniqueAges 16–17 - NCT06467786RecruitingPhase 4
Irinotecan liposomes for advanced small cell lung cancer
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
Xi'an, ShannxiAges 18 years+ - NCT06467500RecruitingPhase 2
Cadonilimab plus chemo for lung cancer after immunotherapy
This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.
YichangAges 18–75 - NCT07833085Recruiting
Imaging test for solid tumors using a special tracer
This study tests a new imaging method that uses a special tracer to find solid tumors in the body. It may help doctors see tumors more clearly and guide treatment.
Wuhan, HubeiAges 18 years+ - NCT06086197RecruitingPhase 2
A drug combo for early relapsed or refractory DLBCL
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
Hangzhou, ZhejiangAges 18 years+ - NCT05410717RecruitingPhase 1
CAR-NK cell therapy for certain solid tumors
This early-phase trial tests a lab-made immune cell treatment for advanced solid tumors that show specific targets (including Claudin 6, GPC3, Mesothelin, or AXL). It may help the immune system better recognize and kill tumor cells, but eligibility depends on test results and your overall health.
Guangzhou, GuangdongAges 18–75 - NCT06476093Recruiting
Radiation plus anlotinib for lung cancer brain spread
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
Lianyungang, JiangsuAges 18–80 - NCT06478225Recruiting
Cell therapy for advanced pancreatic cancer
This trial tests a new cell therapy (BGT007H) for people with advanced pancreatic cancer that has not responded to earlier treatments. The goal is to see if it is safe and can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06477614RecruitingPhase 1
Personalized vaccine for advanced solid tumors
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help your body fight advanced cancer. It is for people whose cancer has not responded to other treatments.
Guanzhou, GuangdongAges 18–80 - NCT07825597Recruiting
Using a special dye to see head and neck cancer during surgery
This trial tests a dye called indocyanine green (ICG) that makes cancer cells glow under a special camera during surgery. It may help doctors remove more cancer and leave healthy tissue alone.
St Louis, MissouriAges 18 years+ - NCT07823829RecruitingPhase 1/Phase 2
CT1190B for large B-cell lymphoma that has returned or not responded to treatment
This study tests a new treatment called CT1190B for people with large B-cell lymphoma that has come back or hasn't responded to at least two prior treatments. The goal is to see if this treatment can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT02445534Recruiting
Registry for cell therapy in non-ischemic dilated heart muscle disease
This is a research registry that follows people with non-ischemic dilated cardiomyopathy (a weakened heart muscle) who are already on the right medications. It helps doctors better understand how cell-based therapy and related care affect heart function over time.
LjubljanaAges 18–65 - NCT07809256RecruitingPhase 3
Combination treatment for advanced lung cancer with a RET gene change
This trial tests a combination of two medicines (pembrolizumab and lenvatinib) for people with advanced non-small cell lung cancer that has a specific RET gene change. The treatment may help slow down or shrink the cancer, and the study checks how well people tolerate it.
Saint PetersburgAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,550 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.